Abbott Laboratories

Abbott Laboratories possessed an incredibly rigorous, deeply entrenched background in massive-scale global healthcare manufacturing and highly complex pharmaceutical commercialization. Managing a heavily diversified, multi-billion dollar portfolio of critical medical products for over a century, this intense background in strategic corporate structuring provided the exact financial blueprint required to successfully execute the historic AbbVie spin-off.

Abbott Laboratories is a massively dominant American healthcare conglomerate and the incredibly powerful corporate founder fundamentally responsible for the historic creation of AbbVie. Operating as an absolute global titan in medical devices, diagnostics, and pharmaceuticals, Abbott controlled a massive, highly lucrative portfolio of proprietary drugs, most notably the blockbuster biologic Humira. In 2013, navigating a highly complex, rapidly evolving regulatory environment and the impending threat of patent cliffs, the corporate leadership aggressively executed an unprecedented, multi-billion dollar corporate spin-off. By completely separating its highly volatile, extremely lucrative research-based pharmaceutical division into an entirely new, independent public entity, Abbott successfully launched AbbVie. This massive strategic maneuver allowed AbbVie to relentlessly focus on aggressive biopharmaceutical innovation while insulating the legacy parent company.